Literature DB >> 27338660

A new motif for inhibitors of geranylgeranyl diphosphate synthase.

Benjamin J Foust1, Cheryl Allen2, Sarah A Holstein2, David F Wiemer3.   

Abstract

The enzyme geranylgeranyl diphosphate synthase (GGDPS) is believed to receive the substrate farnesyl diphosphate through one lipophilic channel and release the product geranylgeranyl diphosphate through another. Bisphosphonates with two isoprenoid chains positioned on the α-carbon have proven to be effective inhibitors of this enzyme. Now a new motif has been prepared with one isoprenoid chain on the α-carbon, a second included as a phosphonate ester, and the potential for a third at the α-carbon. The pivaloyloxymethyl prodrugs of several compounds based on this motif have been prepared and the resulting compounds have been tested for their ability to disrupt protein geranylgeranylation and induce cytotoxicity in myeloma cells. The initial biological studies reveal activity consistent with GGDPS inhibition, and demonstrate a structure-function relationship which is dependent on the nature of the alkyl group at the α-carbon.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bisphosphonate monoester; GGDP synthase; Inhibition; Isoprenoid biosynthesis; Prodrug

Mesh:

Substances:

Year:  2016        PMID: 27338660      PMCID: PMC4955788          DOI: 10.1016/j.bmc.2016.06.019

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  19 in total

Review 1.  Geranylgeranyl diphosphate synthase: an emerging therapeutic target.

Authors:  A J Wiemer; D F Wiemer; R J Hohl
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

Review 2.  The relationship between the chemistry and biological activity of the bisphosphonates.

Authors:  Frank H Ebetino; Anne-Marie L Hogan; Shuting Sun; Maria K Tsoumpra; Xuchen Duan; James T Triffitt; Aaron A Kwaasi; James E Dunford; Bobby L Barnett; Udo Oppermann; Mark W Lundy; Alan Boyde; Boris A Kashemirov; Charles E McKenna; R Graham G Russell
Journal:  Bone       Date:  2011-04-09       Impact factor: 4.398

Review 3.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

4.  Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity.

Authors:  Joo Hwan No; Fernando de Macedo Dossin; Yonghui Zhang; Yi-Liang Liu; Wei Zhu; Xinxin Feng; Jinyoung Anny Yoo; Eunhae Lee; Ke Wang; Raymond Hui; Lucio H Freitas-Junior; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-05       Impact factor: 11.205

5.  Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.

Authors:  Keith Thompson; Michael J Rogers; Fraser P Coxon; Julie C Crockett
Journal:  Mol Pharmacol       Date:  2006-02-24       Impact factor: 4.436

6.  Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.

Authors:  Gábor Németh; Zoltán Greff; Anna Sipos; Zoltán Varga; Rita Székely; Mónika Sebestyén; Zsuzsa Jászay; Szabolcs Béni; Zoltán Nemes; Jean-Luc Pirat; Jean-Noël Volle; David Virieux; Ágnes Gyuris; Katalin Kelemenics; Eva Ay; Janos Minarovits; Susan Szathmary; György Kéri; László Orfi
Journal:  J Med Chem       Date:  2014-05-02       Impact factor: 7.446

7.  Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate.

Authors:  Jerry M Troutman; Kareem A H Chehade; Katarzyna Kiegiel; Douglas A Andres; H Peter Spielmann
Journal:  Bioorg Med Chem Lett       Date:  2004-10-04       Impact factor: 2.823

8.  Triazole-based inhibitors of geranylgeranyltransferase II.

Authors:  Xiang Zhou; Sara V Hartman; Ella J Born; Jacqueline P Smits; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2012-12-01       Impact factor: 2.823

9.  Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.

Authors:  Andrew J Wiemer; Jose S Yu; Larry W Shull; Rocky J Barney; Brian M Wasko; Kimberly M Lamb; Raymond J Hohl; David F Wiemer
Journal:  Bioorg Med Chem       Date:  2008-02-08       Impact factor: 3.641

10.  Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase.

Authors:  Xiang Zhou; Jacqueline E Reilly; Kathleen A Loerch; Raymond J Hohl; David F Wiemer
Journal:  Beilstein J Org Chem       Date:  2014-07-18       Impact factor: 2.883

View more
  10 in total

1.  In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution.

Authors:  Staci L Haney; Yashpal S Chhonker; Michelle L Varney; Geoffrey Talmon; Lynette M Smith; Daryl J Murry; Sarah A Holstein
Journal:  J Pharmacol Exp Ther       Date:  2019-08-16       Impact factor: 4.030

Review 2.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

3.  Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.

Authors:  Nicholas A Lentini; Benjamin J Foust; Chia-Hung Christine Hsiao; Andrew J Wiemer; David F Wiemer
Journal:  J Med Chem       Date:  2018-09-26       Impact factor: 7.446

4.  Stereoselective Synthesis of Homoneryl and Homogeranyl Triazole Bisphosphonates.

Authors:  Robert A Matthiesen; Veronica S Wills; Joseph I Metzger; Sarah A Holstein; David F Wiemer
Journal:  J Org Chem       Date:  2016-09-20       Impact factor: 4.354

5.  Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase.

Authors:  Cheryl Allen; Sandhya Kortagere; Huaxiang Tong; Robert A Matthiesen; Joseph I Metzger; David F Wiemer; Sarah A Holstein
Journal:  Mol Pharmacol       Date:  2017-01-05       Impact factor: 4.436

6.  Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase.

Authors:  Veronica S Wills; Joseph I Metzger; Cheryl Allen; Michelle L Varney; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2017-03-04       Impact factor: 3.641

Review 7.  Prodrugs of pyrophosphates and bisphosphonates: disguising phosphorus oxyanions.

Authors:  Emma S Rudge; Alex H Y Chan; Finian J Leeper
Journal:  RSC Med Chem       Date:  2022-03-01

8.  Amides as bioisosteres of triazole-based geranylgeranyl diphosphate synthase inhibitors.

Authors:  Daniel B Goetz; Michelle L Varney; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2020-06-30       Impact factor: 3.641

Review 9.  Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.

Authors:  Staci L Haney; Veronica S Wills; David F Wiemer; Sarah A Holstein
Journal:  Molecules       Date:  2017-05-27       Impact factor: 4.411

10.  Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma.

Authors:  Staci L Haney; Michelle L Varney; Jacob T Williams; Lynette M Smith; Geoffrey Talmon; Sarah A Holstein
Journal:  Exp Hematol Oncol       Date:  2022-02-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.